Main description:

Antibody-drug conjugates (ADCs) represent a promising therapeutic approach for cancer patients by combining the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of chemotherapeutic drugs. In Antibody-Drug Conjugates, expert researchers provide detailed protocols for many of the key ADC techniques necessary for working in the field. These chapters and methodologies are aimed at the key tasks necessary to identify a suitable target, properly design the mAb, the linker and the payload, as well as to conjugate them in a reproducible and scalable fashion. Written in the highly successful Methods in Molecular Biology (TM) format, these detailed chapters include the kind of practical implementation advice that guarantees quality results.

Authoritative and timely, Antibody-Drug Conjugates aims to further drive ADC development and thus help toward improving cancer treatments of the future.

Contents:

1. Antibody-Drug Conjugate (ADC) Clinical Pipeline: A Review

Ingrid Sassoon and Veronique Blanc

2. Antibody-Drug Conjugate Target Selection: Critical Factors

Neil H. Bander

3. Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy: Internalization and Intracellular Localization

Jay Harper, Shenlan Mao, Patrick Strout, and Adeela Kamal

4. Antibody-Drug Conjugate Payloads

Jan Anderl, Heinz Faulstich, Torsten Hechler and Michael Kulke

5. Linker Technologies for Antibody-Drug Conjugates

Birte Nolting

6. In Vivo Testing of Drug-Linker Stability

Pierre-Yves Abecassis and Celine Amara

7. Pharmacokinetics and ADME Characterizations of Antibody-Drug Conjugates

Kedan Lin, Jay Tibbitts, and Ben-Quan Shen

8. Safe Handling of Cytotoxic Compounds in a Biopharmaceutical Environment

Miriam I. Hensgen and Bernhard Stump

9. Micro- and Mid-Scale Maleimide-Based Conjugation of Cytotoxic Drugs to Antibody Hinge Region Thiols for Tumor Targeting

James E. Stefano, Michelle Busch, Lihui Hou, Anna Park, and Diego A. Gianolio

10. Protocols for Lysine Conjugation

Marie-Priscille Brun and Laurence Gauzy-Lazo

11. Engineering THIOMABs for Site-Specific Conjugation of Thiol-Reactive Linkers

Sunil Bhakta, Helga Raab, and Jagath R. Junutula

12. Enzymatic Antibody Modification by Bacterial Transglutaminase

Patrick Dennler, Roger Schibli, and Eliane Fischer

13. Formulation Development of Antibody-Drug Conjugates

William J. Galush and Aditya A. Wakankar

14. Conjugation Process Development and Scale-Up

Bernhard Stump and Jessica Steinmann

15. Methods for Conjugating Antibodies to Nanocarriers

Anil Wagh and Benedict Law

16. Drug-to-Antibody Ratio (DAR) by UV/Vis Spectroscopy

Yan Chen

17. Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by Hydrophobic Interaction Chromatography and Reversed Phase High Performance Liquid Chromatography

Jun Ouyang

18. Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by LC-ESI-MS

Louisette Basa

19. Determination of Charge Heterogeneity and Level of Unconjugated Antibody by Imaged cIEF

Joyce Lin and Alexandru C. Lazar

20. Risk-Based Scientific Approach for Determination of Extractables/Leachables from Biomanufacturing of Antibody-Drug Conjugates (ADCs)

Weibing Ding